Tissue Inhibitor of Metalloproteinase-2 - Metabolism
Research News and Information

Tuesday, November 24, 2009

Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells.

24 Sep 2009 PURPOSE: An increase of matrix metalloproteinase-2 (MMP-2) has been found to improve outflow through the uveoscleral pathway. This experiment was designed to test whether reduction of inhibitor of nuclear factor kappa B alpha (IkappaBalpha) levels ... Read more...

Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas.

30 Aug 2009 AIMS: The balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) is involved in the morphogenesis of normal salivary gland as well as in the mechanisms of tumour invasion and metastasis. The role of MMPs and TIMPs in ... Read more...

Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain.

25 Aug 2009 The present study was designed to investigate the role of matrix metalloproteinases (MMPs) in the immature brain and the long term effects of early MMPs inhibition after hypoxic-ischemic (HI) injury. HI was induced by unilateral ligation of the ... Read more...

Latest indexed articles for 'Tissue Inhibitor of Metalloproteinase-2 - Metabolism'

These are the very latest articles for this heading:

• Suppression of IkappaBalpha increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells. 24 Sep 2009
• Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. 30 Aug 2009
• Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. 25 Aug 2009
• Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. 21 Aug 2009
• Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. 30 Jul 2009
• Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions. 30 Jul 2009
• Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma. 30 Jul 2009
• Response of extracellular matrix regulators in mouse lung after exposure to photons, protons and simulated solar particle event protons. 29 Jun 2009
• Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. 29 Jun 2009
• Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. 9 Jun 2009
• Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. 30 May 2009
• Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. 30 May 2009
• [Effects of allicin on invasion and metastasis of colon cancer LoVo cell line in vitro] 24 May 2009
• Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. 29 Apr 2009
• Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. 28 Apr 2009
• The definition of fibrogenic processes in fibroblastic foci of idiopathic pulmonary fibrosis based on morphometric quantification of extracellular matrices. 20 Apr 2009
• Ginkgo biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells. 30 Mar 2009
• Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. 11 Mar 2009
• Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. 8 Mar 2009
• Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration. 27 Feb 2009

See a longer list of these articles.

Technical information about 'Tissue Inhibitor of Metalloproteinase-2'

Definition: A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a 21-kDa nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase A by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of TIMP-2 has been shown to inhibit invasive and metastatic activity of tumor cells and decrease tumor growth in vivo.

Registry Number: 127497-59-0

Descriptor UI: D019716

Alternative terms: Tissue Inhibitor of Metalloproteinase-2; Metalloproteinase-2 Tissue Inhibitor; Tissue Inhibitor of Metalloproteinase 2; TIMP-2;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.926.500;

History Note: 1998; see TISSUE INHIBITOR OF METALLOPROTEINASE-2 (NM) 1989-1997